This company has shut down. ReNAgade Therapeutics is no longer operating — its last tracked round was a Series A in 2023.
Explore the Startup GraveyardReNAgade Therapeutics focuses on the boundless potential of RNA therapeutics to treat disease.
ReNAgade Therapeutics has raised $300.0M in total funding. The most recent round was Series A. The last funding was announced in May 2023.
ReNAgade Therapeutics's investors include MPM Capital, F2 Ventures.
ReNAgade Therapeutics is headquartered in Cambridge, United States.
ReNAgade Therapeutics focuses on the boundless potential of RNA therapeutics to treat disease.
ReNAgade Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ReNAgade Therapeutics — Funding & Investors." VCBacked, May 23, 2023, https://www.vcbacked.co/company/renagade-therapeutics. Accessed August 14, 2026.
VCBacked. (2023). ReNAgade Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/renagade-therapeutics
{{cite web |title=ReNAgade Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/renagade-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated